Mitochondria in Retinal Ganglion Cells

About the Research Project
Program
Award Type
Standard
Award Amount
$182,000
Active Dates
July 01, 2025 - June 30, 2027
Grant ID
G2025003S
Goals
This project aims to characterize the biology of mitochondria in the RGC dendritic compartment, with particular emphasis on how these organelles are turned over before and after optic nerve damage.
Summary
Retinal ganglion cells receive input from a tree-like dendritic arbor that exhibits pathology after optic nerve damage. This study examines the biology of energy producing organelles called mitochondria in arbor pathology including how specialized cells called microglia participate in this process.
Unique and Innovative
This marks the first time anyone has mapped mitochondria in the dendritic arbors of ganglion cells.
Foreseeable Benefits
Ganglion cells are also really sensitive to abnormalities in mitochondria – the powerhouse organelle in every cells that makes energy. It is so profound, that mutations that affect mitochondrial function in every cell lead to optic nerve disease as sometimes the only consequence. We hope that this study will help us better understand why ganglion cells are so sensitive to mitochondrial function which could lead to the development of novel treatments to enhance ganglion cell resilience.
Related Grants
National Glaucoma Research
Role of a Key Gene, Angptl7, in Steroid-Induced Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
W. Daniel Stamer, PhD
Current Organization
Duke University
Role of a Key Gene, Angptl7, in Steroid-Induced Glaucoma
Active Dates
July 01, 2025 - June 30, 2027

Principal Investigator
W. Daniel Stamer, PhD
Current Organization
Duke University
National Glaucoma Research
Assessment of Vascular Resistance in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Brad Fortune, OD, PhD
Current Organization
Legacy Devers Eye Institute
Assessment of Vascular Resistance in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027

Principal Investigator
Brad Fortune, OD, PhD
Current Organization
Legacy Devers Eye Institute
National Glaucoma Research
Interleukin-10 As a Neuroprotective Factor in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Tatjana Jakobs, MD
Current Organization
The Schepens Eye Research Institute, Mass. Eye and Ear
Interleukin-10 As a Neuroprotective Factor in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027

Principal Investigator
Tatjana Jakobs, MD
Current Organization
The Schepens Eye Research Institute, Mass. Eye and Ear